SIMPLIVIA Hazardous Drug Locking Capacity of Activated Elana A. Slutsky Smith Simplivia Healthcare Ltd., Kiryat Shmona, Israel Carbon-Based CSTD: 3 Approaches

Objective

Closed system transfer devices (CSTDs) incorporate various hazardous drug (HD) vapor containment technologies. While containment capacity of balloon-based devices is limited to balloon volume, that of devices with activated carbon drug-binding mechanical barriers is independent of physical size (Figure 1). Studies have shown that such devices can contain at least 75 L of HD vapors¹ (> 25 µg) but have not determined upper limits of containment capacity.

The aim was to calculate and experimentally determine the maximum HD vapor adsorption capacity of an activated carbon matrix-based CSTD.



B

Activated

carbon

Ethyl acetate

C1

A

Results

5-Fluorouracil (5-FU) has the highest vapor concentration of HDs at room temperature: 339 ng/L.

Using ethyl acetate uptake (method 1), adsorption capacity was determined to be 17 mg per device For PGME.

Mean adsorption capacity was 4.2 mg by mass increase (method 2a) and 25.9 mg by

Drug	Gas phase conc. at 25°C (ng/l)
Thiotepa	1.16x10 ²
Cyclophosphamide	2.78 x10 ²
Cisplatin	8.55 x10 ⁻¹⁶
Carboplatin	2.25 x10 ⁻²
Cormusting	6 12

Figure 1 Containment capacity of balloon-based devices (A) is limited by balloon volume, while activated carbon in drug-binding mechanical barrier devices (B) contain microscopic pores that bind hazardous molecules inside, invisible to the human eye.

Methods

Maximum adsorption capacity was determined using three different approaches:

Method 1

Weight % adsorption capacity specifications using ethyl acetate uptake were obtained from the activated carbon manufacturer (Figure 2). Adsorption capacity per device was calculated using mean carbon mass per device (n = 10 on analytical balance).

Figure 2 Schematic representation of ethyl acetate adsorption capacity method. Dry activated carbon is maintained in a desiccator in the presence of ethyl acetate and weight increase is monitored.

time till release (method 2b).

Table 1Calculated gas phase concentrations of most volatile
hazardous drugs in closed containers at room
temperature. 5-FU is the largest.

Mass increase by time until detection was calculated as follows:

Time×Flow rate×Concentration=Adsorbed mass

20.3 s × 13 L/min × 1 min/60 s × 5.9 mg/L = 25.9 mg

Table 2Mass increase and time until detection for 3 samplesof activated carbon matrices subjected to PGMEvapor flow (methods 2a and 2b).

Volume of 5-FU vapors required to reach maximum adsorption capacity is equivalent to adsorption capacity divided by vapor concentration (Table 3):

Adsorption capacity [mg] ×	10 ⁶ ng/mg	
	=	Vapor volume capacity
339 ng/L		

Carmustine6.42Etoposide1.43 x10-185-Fluorouracil3.39 x102

Sample	1	2	3
Mass increase (mg)	3.8	4.1	4.7
Mean mass increase (mg)		4.2	
Time until detection (s)	21	14	26
Mean time until detection (s)	20.3		

Method	Adsorption capacity (mg)	Vapor volume capacity (L)
1	17	50,000
2a	4.2	12,000
2b	25.9	76,000

Method 2

Vapors of propylene glycol methyl ether (PGME) surrogate were produced in a Dreschel-type device and pumped at constant concentration (5.9 mg/L) and flow (13 L/min) through a CSTD containing the carbon drug-binding matrix until release was detected by volatile organic compound detector (Figure 3).




Figure 3 (A) Schematic representation of experimental set up for adsorption capacity determination by methods 2a and 2b. Air was supplied at constant flow through a container containing liquid PGME and PGME vapor. Vapor concentration above the liquid was 5.9 mg/L. VA = Vial Adaptor containing an activated carbon drug-binding mechanical barrier. Air flow was from the spike of the Vial Adaptor towards the activated carbon component. (B) Air path (in green) of Vial Adaptor through which the challenge vapor was flown.

Method 2a: Carbon matrices from 3 devices were weighed before and after the procedure. Using mass increase, maximum adsorption capacity was determined. Method 2b: Using time until release, maximum adsorption capacity was determined, using the equation:

Time×Flow rate×Concentration=Adsorbed mass

Table 3Calculated volumes of 5-FU vapors required toreach adsorption capacity, according to resultsof each method.

Discussion & Conclusions

Three approaches estimated maximum adsorption capacity per activated carbon-based CSTD corresponding to 12,000-76,000 L of worst-case HD vapors, 160-1000 times higher than the volume used to challenge the device in previous studies (75 L). Volumes are expected to be higher for HDs other than 5-FU.

Considering that a CSTD typically will not have more than 100-200 ml of drug vapor forced through the activated carbon matrix, the CSTD tested provides a safety margin of 60,000-fold or more.

Sponsorship

Sponsored by Simplivia Healthcare Ltd, the manufacturer of Chemfort® CSTD.

Vapor concentrations of HDs at room temperature were calculated using published Henry's constants². Theoretical and experimental surrogate adsorption capacities were used to determine the vapor volume of a worst-case real HD required to reach this capacity.

Presenting Author: Elana Slutsky Smith, Ph.D | elana.slutskysmith@simplivia.com

References ¹ Levin G, Sessink PJM, J. Oncol. Pharm. Pract. 2021; doi: 10.1177/10781552211030682. Epub ahead of print. ² Wilkinson AS, Allwood MC, et al. PLoS One. 2018;13(10): e0205263.